跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 1,405 条关于
“VYVGART SC”
全部
1,405
临床试验
868
药物
370
机构
12
资讯
155
10个月前
Health Canada Approves VYVGART SC as First Novel CIDP Treatment in Three Decades
9个月前
argenx Discontinues Phase 3 UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease Following Futility Analysis
去年
FcRn Inhibitors Show Promise in Autoimmune Disease Treatment, Market Set for Growth
去年
Argenx Showcases Long-term Efficacy and Safety Data for VYVGART at AAN 2025 Meeting
2年前
VYVGART Hytrulo Approved by FDA as First FcRn Blocker for CIDP Treatment
去年
Efgartigimod Shows Efficacy in CIDP Patients Regardless of Prior Treatment
去年
Handok's Vyvgart Receives Approval for Generalized Myasthenia Gravis Treatment in South Korea
3个月前
FDA Approves Argenx's Vyvgart Label Expansion to All Adult gMG Patients in May 2026
去年
VYVGART Achieves Primary Endpoint in Phase 3 Trial for AChR-Ab Seronegative Myasthenia Gravis
去年
European Commission Approves Darzalex SC with VRd for Newly Diagnosed Multiple Myeloma
第 1 页,共 16 页
上一页
下一页